1.Contralateral Breast Symmetrisation in Immediate Prosthetic Breast Reconstruction after Unilateral Nipple-Sparing Mastectomy: The Tailored Reduction/Augmentation Mammaplasty.
Marzia SALGARELLO ; Giuseppe VISCONTI ; Liliana BARONE-ADESI ; Gianluca FRANCESCHINI ; Riccardo MASETTI
Archives of Plastic Surgery 2015;42(3):302-308
BACKGROUND: In the literature on nipple-sparing mastectomy (NSM) with one-stage immediate implant reconstruction, contralateral symmetrisation has drawn little attention, with many surgeons still performing standard cosmetic mammaplasty procedures. However, standard implant-based mammaplasty usually does not result in proper symmetry with the mastectomy side, especially regarding breast projection, overall shape, and volume distribution. METHODS: We retrospectively reviewed 19 consecutive patients undergoing unilateral NSM with immediate prosthetic reconstruction and contralateral simultaneous symmetrisation by using the tailored reduction/augmentation mammaplasty technique between June 2012 and August 2013. RESULTS: The average follow-up time was 13 months (range, 10-24 months). No major complications, such as infection, haematoma, and nipple-areola complex necrosis, were experienced. CONCLUSIONS: Our experience suggests that simultaneous contralateral symmetrisation with tailored reduction/augmentation mammaplasty after unilateral immediate implant reconstruction after NSM facilitates durable and pleasant symmetric outcomes.
Breast Implants
;
Breast*
;
Female
;
Follow-Up Studies
;
Humans
;
Mammaplasty*
;
Mastectomy*
;
Mastectomy, Subcutaneous
;
Necrosis
;
Retrospective Studies
2.Twenty-four-hour serum creatinine variation is associated with poor outcome in the novel coronavirus disease 2019 (COVID-19) patients
Gaetano ALFANO ; Annachiara FERRARI ; Francesco FONTANA ; Giacomo MORI ; Giulia LIGABUE ; Silvia GIOVANELLA ; Riccardo MAGISTRONI ; Marianna MESCHIARI ; Erica FRANCESCHINI ; Marianna MENOZZI ; Gianluca CUOMO ; Gabriella ORLANDO ; Antonella SANTORO ; Margherita DI GAETANO ; Cinzia PUZZOLANTE ; Federica CARLI ; Andrea BEDINI ; Jovana MILIC ; Cristina MUSSINI ; Gianni CAPPELLI ; Giovanni GUARALDI ;
Kidney Research and Clinical Practice 2021;40(2):231-240
Background:
The development of acute kidney injury (AKI) in patients with coronavirus disease 2019 (COVID-19) is associated with a high risk of death. Published data demonstrate the possibility of severe kidney injury in patients suffering from COVID-19. However, these data are still controversial.
Methods:
A total of 1,280 patients with a proven diagnosis of COVID-19 were included in our study. COVID-19 was confirmed in all patients using reverse transcriptase polymerase chain reaction test of a nasopharyngeal swab, and based on the typical computed tomography findings. Demographic data, underlying comorbidities, and laboratory blood tests were assessed. We assessed the incidence of AKI and its associated mortality defined by survival status at discharge.
Results:
Proteinuria was identified with 648 patients (50.6%) with COVID-19. AKI was identified in 371 patients (29.0%). Ten of these patients (2.7%) required dialysis. The risk factors for AKI included age of > 65 years, augmentation of C-reactive protein, ferritin and an increase in values of activated partial thromboplastin time. Overall, 162 of the 1,280 hospitalized patients (12.7%) and 111 of the 371 patients (29.9%) with AKI did not survive. The hazard ratio (HR) for mortality was 3.96 (95% confidence interval, 2.83–5.54) for patients with AKI vs. no AKI.
Conclusion
AKI was a relatively common finding among patients with COVID-19. The risk factors for AKI in COVID-19 included old age, the inflammatory response, the severity of lung involvement, and disseminated intravascular coagulation. These same factors, in addition to arterial hypertension, were found to increase the risk of mortality.
3.Twenty-four-hour serum creatinine variation is associated with poor outcome in the novel coronavirus disease 2019 (COVID-19) patients
Gaetano ALFANO ; Annachiara FERRARI ; Francesco FONTANA ; Giacomo MORI ; Giulia LIGABUE ; Silvia GIOVANELLA ; Riccardo MAGISTRONI ; Marianna MESCHIARI ; Erica FRANCESCHINI ; Marianna MENOZZI ; Gianluca CUOMO ; Gabriella ORLANDO ; Antonella SANTORO ; Margherita DI GAETANO ; Cinzia PUZZOLANTE ; Federica CARLI ; Andrea BEDINI ; Jovana MILIC ; Cristina MUSSINI ; Gianni CAPPELLI ; Giovanni GUARALDI ;
Kidney Research and Clinical Practice 2021;40(2):231-240
Background:
The development of acute kidney injury (AKI) in patients with coronavirus disease 2019 (COVID-19) is associated with a high risk of death. Published data demonstrate the possibility of severe kidney injury in patients suffering from COVID-19. However, these data are still controversial.
Methods:
A total of 1,280 patients with a proven diagnosis of COVID-19 were included in our study. COVID-19 was confirmed in all patients using reverse transcriptase polymerase chain reaction test of a nasopharyngeal swab, and based on the typical computed tomography findings. Demographic data, underlying comorbidities, and laboratory blood tests were assessed. We assessed the incidence of AKI and its associated mortality defined by survival status at discharge.
Results:
Proteinuria was identified with 648 patients (50.6%) with COVID-19. AKI was identified in 371 patients (29.0%). Ten of these patients (2.7%) required dialysis. The risk factors for AKI included age of > 65 years, augmentation of C-reactive protein, ferritin and an increase in values of activated partial thromboplastin time. Overall, 162 of the 1,280 hospitalized patients (12.7%) and 111 of the 371 patients (29.9%) with AKI did not survive. The hazard ratio (HR) for mortality was 3.96 (95% confidence interval, 2.83–5.54) for patients with AKI vs. no AKI.
Conclusion
AKI was a relatively common finding among patients with COVID-19. The risk factors for AKI in COVID-19 included old age, the inflammatory response, the severity of lung involvement, and disseminated intravascular coagulation. These same factors, in addition to arterial hypertension, were found to increase the risk of mortality.